Jump to content
  • Sign Up
0
Scott Adams

Biotech vets back $22M A round for neuroscience start-up - FierceBiotech

Rate this topic

Recommended Posts

Biotech vets back $22M A round for neuroscience start-up

FierceBiotech

The last heard from Alba was a press release back in early 2011 laying out an option deal that Cephalon had struck for acquiring all the assets related to its lead therapy, larazotide acetate, following a Phase IIb for celiac disease.

and more »

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×